Try our beta test site
1334 studies found for:    lymphoma [CONDITION] OR CLL [CONDITION] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma
Interventions: Drug: TGR-1202;   Drug: Ibrutinib
2 Recruiting Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Condition: LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Intervention: Biological: CART 19
3 Not yet recruiting Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Biological: Obinutuzumab
4 Recruiting A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: IPI-145 (duvelisib);   Drug: Ofatumumab
5 Recruiting A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Conditions: CLL (Chronic Lymphocytic Leukemia);   SLL (Small Lymphocytic Lymphoma)
Interventions: Drug: Ibrutinib;   Drug: Fludarabine
6 Recruiting Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Conditions: CLL;   SLL
Interventions: Drug: Ofatumumab;   Drug: High-Dose Methylprednisolone;   Drug: Alemtuzumab
7 Not yet recruiting A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Condition: Lymphoma, Follicular
Interventions: Biological: SAIT101;   Biological: MabThera®
8 Recruiting Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
Condition: B-cell Lymphoma
Intervention: Drug: Ibrutinib and immunochemotherapies
9 Recruiting Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma
Condition: Lymphoma
Intervention: Biological: CD19-targeted CAR-T cells
10 Recruiting Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Conditions: Non-Hodgkin's Lymphoma;   B-Cell ALL;   B-Cell CLL
Interventions: Genetic: CD19.CAR-CD28Z T Cells - dose escalation 2;   Genetic: CD19.CAR-CD28Z T Cells - dose escalation 1
11 Not yet recruiting A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma
Interventions: Drug: Cirmtuzumab;   Drug: Ibrutinib;   Drug: Cirmtuzumab plus ibrutinib
12 Recruiting Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma
Condition: Lymphoma
Intervention: Biological: The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)
13 Recruiting A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Blinatumomab
14 Recruiting Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: peripheral blood stem cell transplantation;   Radiation: irradiation therapy;   Biological: G-CSF;   Drug: Cytarabine
15 Not yet recruiting Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
Conditions: T-Cell Lymphoma Relapsed;   T-Cell Lymphoma Refractory
Intervention: Drug: Avelumab
16 Recruiting Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL
Condition: Lymphoma Non-Hodgkin
Intervention: Drug: Copanlisib (BAY80-6946)
17 Recruiting A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Condition: Follicular Lymphoma
Interventions: Biological: PF-05280586;   Biological: MabThera®
18 Recruiting Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT
Condition: Mantle-cell Lymphoma
Intervention: Drug: subcutaneous Rituximab
19 Recruiting Indolent Non Follicular Lymphomas Prognostic Project
Condition: Indolent B-Cell Lymphomas
Intervention: Other: Any treatment, watch and wait policy included
20 Recruiting Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: Rituximab, bendamustine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.